GlassScriptPhysician profile
Aida Haddad
NPI 1801380225
$1,108.29
in general payments reported to CMS, 2019-2025
11 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $27.46 · 2021: $51.17 · 2022: $46.14 · 2023: $261 · 2024: $51.68 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $182.72 | 2019-2023 | Rocklatan |
| Bard Peripheral Vascular, INC. | $182.32 | 2023 | Trek |
| Lilly USA, LLC | $181.60 | 2019 | |
| Sight Sciences, INC. | $124.11 | 2025 | Tearcare System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.14 | 2019 | |
| Novo Nordisk INC | $101.53 | 2019 | |
| Glaukos Corporation | $99.22 | 2019-2023 | Istent Inject Trabecular Micro-Bypass System, Istent Inject Trabecular Micro-Bypass System |
| Harrow Eye, LLC | $51.68 | 2024 | Vevye |
| Horizon Therapeutics Plc | $29.86 | 2021 | |
| Travere Therapeutics, INC. | $17.73 | 2023 | Cholbam |
| Bausch & Lomb Americas INC. | $15.38 | 2023 | Envista Mx60 Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aida Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.